NCT06155760View on ClinicalTrials.gov

Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis

NANot yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 25, 2023

Primary Completion Date

February 27, 2025

Study Completion Date

February 27, 2025

Conditions
Severe Alcoholic Hepatitis
Interventions
DRUG

Prednisolone

10mg of prednisolone plus standard medical therapy for 60 days

OTHER

Standard Medical therapy

IV Albumin, Diuretics, Multi vitamins as per clinicians decision

DRUG

Placebo

Placebo

Trial Locations (1)

110070

Institute of Liver & Biliary Sciences (ILBS), New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT06155760 - Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis | Biotech Hunter | Biotech Hunter